E2F inhibition synergizes with paclitaxel in lung cancer cell lines

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Kurtyka, Courtney A ^a   Chen, Lu ^a   Cress, W Douglas ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GEMCITABINE; HLM 006474; PACLITAXEL; PROTEIN INHIBITOR; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR E2F; TRANSCRIPTION FACTOR E2F3; TRANSCRIPTION FACTOR E2F3A; TRANSCRIPTION FACTOR E2F3B; UNCLASSIFIED DRUG; AMINOPYRIDINE DERIVATIVE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; E2F3 PROTEIN, HUMAN; HLM006474; QUINOLINOL DERIVATIVE;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SENSITIVITY; IC 50; LUNG CANCER CELL LINE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MONOTHERAPY; PROTEIN CONTENT; PROTEIN INDUCTION; ANALOGS AND DERIVATIVES; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; HUMAN; IC50; LUNG TUMOR; METABOLISM; NON SMALL CELL LUNG CANCER; PATHOLOGY; SMALL CELL LUNG CANCER; TUMOR CELL LINE;

AMINOPYRIDINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; DEOXYCYTIDINE; DRUG SYNERGISM; E2F3 TRANSCRIPTION FACTOR; HUMANS; HYDROXYQUINOLINES; INHIBITORY CONCENTRATION 50; LUNG NEOPLASMS; PACLITAXEL; RNA, SMALL INTERFERING; SMALL CELL LUNG CARCINOMA;

EID: 84901306391     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0096357     Document Type: Article

References (52)

1. Sherr CJ (1996) Cancer cell cycles. Science 274: 1672-1677.
2. Nevins JR (2001) The Rb/E2F pathway and cancer. Hum Mol Genet 10: 699-703.
3. Malumbres M, Barbacid M (2009) Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 9: 153-166.
4. Besson A, Dowdy SF, Roberts JM (2008) CDK inhibitors: cell cycle regulators and beyond. Dev Cell 14: 159-169. (Pubitemid 351189186)
5. Chen HZ, Tsai SY, Leone G (2009) Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer 9: 785-797.
6. Taubert S, Gorrini C, Frank SR, Parisi T, Fuchs M, et al. (2004) E2F-dependent histone acetylation and recruitment of the Tip60 acetyltransferase complex to chromatin in late G1. Mol Cell Biol 24: 4546-4556. (Pubitemid 44109137)
7. Lang SE, McMahon SB, Cole MD, Hearing P (2001) E2F transcriptional activation requires TRRAP and GCN5 cofactors. J Biol Chem 276: 32627-32634.
8. Harbour JW, Dean DC (2000) The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev 14: 2393-2409.
9. Humbert PO, Verona R, Trimarchi JM, Rogers C, Dandapani S, et al. (2000) E2f3 is critical for normal cellular proliferation. Genes Dev 14: 690-703. (Pubitemid 30176823)
10. Wu L, Timmers C, Maiti B, Saavedra HI, Sang L, et al. (2001) The E2F1-3 transcription factors are essential for cellular proliferation. Nature 414: 457-462. (Pubitemid 34173728)
11. Leone G, Sears R, Huang E, Rempel R, Nuckolls F, et al. (2001) Myc requires distinct E2F activities to induce S phase and apoptosis. Mol Cell 8: 105-113. (Pubitemid 32772909)
12. Kong LJ, Chang JT, Bild AH, Nevins JR (2007) Compensation and specificity of function within the E2F family. Oncogene 26: 321-327. (Pubitemid 46122822)
13. Leone G, DeGregori J, Yan Z, Jakoi L, Ishida S, et al. (1998) E2F3 activity is regulated during the cell cycle and is required for the induction of S phase. Genes Dev 12: 2120-2130. (Pubitemid 28348036)
14. He L, Yang H, Ma Y, Pledger WJ, Cress WD, et al. (2008) Identification of Aurora-A as a direct target of E2F3 during G2/M cell cycle progression. J Biol Chem 283: 31012-31020.
15. Zhu W, Giangrande PH, Nevins JR (2004) E2Fs link the control of G1/S and G2/M transcription. EMBO J 23: 4615-4626. (Pubitemid 39657861)
16. Hu Q, Lu JF, Luo R, Sen S, Maity SN (2006) Inhibition of CBF/NF-Y mediated transcription activation arrests cells at G2/M phase and suppresses expression of genes activated at G2/M phase of the cell cycle. Nucleic Acids Res 34: 6272-6285. (Pubitemid 44942748)
17. Leone G, Nuckolls F, Ishida S, Adams M, Sears R, et al. (2000) Identification of a novel E2F3 product suggests a mechanism for determining specificity of repression by Rb proteins. Mol Cell Biol 20: 3626-3632. (Pubitemid 30243908)
18. Adams MR, Sears R, Nuckolls F, Leone G, Nevins JR (2000) Complex transcriptional regulatory mechanisms control expression of the E2F3 locus. Mol Cell Biol 20: 3633-3639. (Pubitemid 30243909)
19. He Y, Armanious MK, Thomas MJ, Cress WD (2000) Identification of E2F-3B, an alternative form of E2F-3 lacking a conserved N-terminal region. Oncogene 19: 3422-3433. (Pubitemid 30479337)
20. Chong JL, Tsai SY, Sharma N, Opavsky R, Price R, et al. (2009) E2f3a and E2f3b contribute to the control of cell proliferation and mouse development. Mol Cell Biol 29: 414-424.
21. Danielian PS, Friesenhahn LB, Faust AM, West JC, Caron AM, et al. (2008) E2f3a and E2f3b make overlapping but different contributions to total E2f3 activity. Oncogene 27: 6561-6570.
22. Cooper CS, Nicholson AG, Foster C, Dodson A, Edwards S, et al. (2006) Nuclear overexpression of the E2F3 transcription factor in human lung cancer. Lung Cancer 54: 155-162. (Pubitemid 44764914)
23. Matsumura N, Huang Z, Baba T, Lee PS, Barnett JC, et al. (2009) Yin yang 1 modulates taxane response in epithelial ovarian cancer. Mol Cancer Res 7: 210-220.
24. Tordai A, Wang J, Andre F, Liedtke C, Yan K, et al. (2008) Evaluation of biological pathways involved in chemotherapy response in breast cancer. Breast Cancer Res 10: R37.
25. ACS (2010) Cancer Facts and Figures 2010. Atlanta, GA: American Cancer Society. pp. 1-68.
26. Shimizu E, Coxon A, Otterson GA, Steinberg SM, Kratzke RA, et al. (1994) RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma. Oncogene 9: 2441-2448. (Pubitemid 24254018)
27. Beasley MB, Lantuejoul S, Abbondanzo S, Chu WS, Hasleton PS, et al. (2003) The P16/cyclin D1/Rb pathway in neuroendocrine tumors of the lung. Hum Pathol 34: 136-142. (Pubitemid 36258804)
28. Xu HJ, Hu SX, Cagle PT, Moore GE, Benedict WF (1991) Absence of retinoblastoma protein expression in primary non-small cell lung carcinomas. Cancer Res 51: 2735-2739.
29. Otterson GA, Kratzke RA, Coxon A, Kim YW, Kaye FJ (1994) Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene 9: 3375-3378.
30. Shapiro GI, Edwards CD, Kobzik L, Godleski J, Richards W, et al. (1995) Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res 55: 505-509.
31. Shapiro GI, Park JE, Edwards CD, Mao L, Merlo A, et al. (1995) Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines. Cancer Res 55: 6200-6209.
32. Kelley MJ, Nakagawa K, Steinberg SM, Mulshine JL, Kamb A, et al. (1995) Differential inactivation of CDKN2 and Rb protein in non-small-cell and small-cell lung cancer cell lines. J Natl Cancer Inst 87: 756-761.
33. Guha M (2013) Blockbuster dreams for Pfizer's CDK inhibitor. Nat Biotechnol 31: 187.
34. Flaherty KT, Lorusso PM, Demichele A, Abramson VG, Courtney R, et al. (2012) Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res 18: 568-576.
35. Schwartz GK, LoRusso PM, Dickson MA, Randolph SS, Shaik MN, et al. (2011) Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br J Cancer 104: 1862-1868.
36. Ma Y, Kurtyka CA, Boyapalle S, Sung SS, Lawrence H, et al. (2008) A small-molecule E2F inhibitor blocks growth in a melanoma culture model. Cancer Res 68: 6292-6299.
37. Porlan E, Morante-Redolat JM, Marques-Torrejon MA, Andreu-Agullo C, Carneiro C, et al. (2013) Transcriptional repression of Bmp2 by p21(Waf1/ Cip1) links quiescence to neural stem cell maintenance. Nat Neurosci 16: 1567-1575.
38. Zheng Y, Devitt C, Liu J, Iqbal N, Skapek SX (2013) Arf induction by Tgfbeta is influenced by Sp1 and C/ebpbeta in opposing directions. PLoS One 8: e70371.
39. Conklin JF, Baker J, Sage J (2012) The RB family is required for the self-renewal and survival of human embryonic stem cells. Nat Commun 3: 1244.
40. Sangwan M, McCurdy SR, Livne-Bar I, Ahmad M, Wrana JL, et al. (2012) Established and new mouse models reveal E2f1 and Cdk2 dependency of retinoblastoma, and expose effective strategies to block tumor initiation. Oncogene 31: 5019-5028.
41. Hurst CD, Tomlinson DC, Williams SV, Platt FM, Knowles MA (2008) Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification. Oncogene 27: 2716-2727. (Pubitemid 351581468)
42. Corsino P, Horenstein N, Ostrov D, Rowe T, Law M, et al. (2009) A novel class of cyclin-dependent kinase inhibitors identified by molecular docking act through a unique mechanism. J Biol Chem 284: 29945-29955.
43. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
44. Ma Y, Chen L, Wright GM, Pillai SR, Chellappan SP, et al. (2010) CDKN1C negatively regulates RNA polymerase II C-terminal domain phosphorylation in an E2F1-dependent manner. J Biol Chem 285: 9813-9822.
45. Chen L, Chen DT, Kurtyka C, Rawal B, Fulp WJ, et al. (2012) Tripartite motif containing 28 (Trim28) can regulate cell proliferation by bridging HDAC1/E2F interactions. J Biol Chem 287: 40106-40118.
46. Weintraub SJ, Prater CA, Dean DC (1992) Retinoblastoma protein switches the E2F site from positive to negative element. Nature 358: 259-261.
47. Weintraub SJ, Chow KN, Luo RX, Zhang SH, He S, et al. (1995) Mechanism of active transcriptional repression by the retinoblastoma protein. Nature 375: 812-815.
48. Chong JL, Wenzel PL, Saenz-Robles MT, Nair V, Ferrey A, et al. (2009) E2f1-3 switch from activators in progenitor cells to repressors in differentiating cells. Nature 462: 930-934.
49. He S, Cook BL, Deverman BE, Weihe U, Zhang F, et al. (2000) E2F is required to prevent inappropriate S-phase entry of mammalian cells. Mol Cell Biol 20: 363-371. (Pubitemid 30002577)
50. Bild AH, Yao G, Chang JT, Wang Q, Potti A, et al. (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439: 353-357. (Pubitemid 43128862)
51. Dickson MA, Tap WD, Keohan ML, D'Angelo SP, Gounder MM, et al. (2013) Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol 31: 2024-2028.
52. Leonard JP, LaCasce AS, Smith MR, Noy A, Chirieac LR, et al. (2012) Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood 119: 4597-4607.